Prospective study demonstrates safety and efficacy of DCB strategy in high-risk stent failure individuals, suggesting effective alternatives.
This prospective study demonstrates that a DCB strategy for CTO patients with HR-SF is feasible and safe. A DCB-only approach resulted in favorable early outcomes for most patients. In the case of suboptimal initial results, the redo-DCB strategy emerged as a promising alternative to extensive stenting.
No takes yet. Share an insight, caveat, or question.
Cocco et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: